Literature DB >> 27796783

Structural and functional aspects of decorsin and its analog as recognized by integrin αIIbβ3.

Xingzhen Lao1, Jingxiao Bao1, Tingting Yu1, Qingqing Li1, Heng Zheng2.   

Abstract

Decorsin is an antagonist of platelet glycoprotein integrin αIIbβ3 on platelets; the protein is 39 amino acids long with three disulfide bridges in its tertiary structure. To demonstrate decorsin's mechanism of action, we applied the computational virtual technique and platelet aggregation inhibition assay, which showed that the flanking amino-acid residues of the Arg-Gly-Asp (RGD) motif play an important role in platelet aggregation. The computational simulations revealed that the RGD motif mainly contributes to the stability of the complex when decorsion interacts with integrin αIIbβ3. However, the C-terminal residues, such as 34A→W and 35D→R, was also found to possibly play a key role in their binding structures. Moreover, we produced a decorsin analog (A34W plus D35R decorsin), in which the 34A (alanine) and 35D (aspartic acid) residues were respectively substituted by W (tryptophan) and R (arginine). This isoform was then recombinantly expressed in Escherichia coli. Intriguingly, this mutant type showed higher anti-platelet aggregation activity than the wildtype. Our study may further contribute to finding decorsin mutants with higher anti-platelet aggregation activity.

Entities:  

Keywords:  Decorsin; Integrin; Mutation; RGD motif

Mesh:

Substances:

Year:  2016        PMID: 27796783     DOI: 10.1007/s00894-016-3147-1

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  27 in total

1.  ZDOCK: an initial-stage protein-docking algorithm.

Authors:  Rong Chen; Li Li; Zhiping Weng
Journal:  Proteins       Date:  2003-07-01

2.  Closed headpiece of integrin αIIbβ3 and its complex with an αIIbβ3-specific antagonist that does not induce opening.

Authors:  Jieqing Zhu; Jianghai Zhu; Ana Negri; Davide Provasi; Marta Filizola; Barry S Coller; Timothy A Springer
Journal:  Blood       Date:  2010-08-02       Impact factor: 22.113

3.  PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data.

Authors:  Daniel R Roe; Thomas E Cheatham
Journal:  J Chem Theory Comput       Date:  2013-06-25       Impact factor: 6.006

4.  Recognition site for the platelet receptor is present on the 15-residue carboxy-terminal fragment of the gamma chain of human fibrinogen and is not involved in the fibrin polymerization reaction.

Authors:  M Kloczewiak; S Timmons; J Hawiger
Journal:  Thromb Res       Date:  1983-01-15       Impact factor: 3.944

Review 5.  Antiplatelet therapy.

Authors:  A I Schafer
Journal:  Am J Med       Date:  1996-08       Impact factor: 4.965

6.  Impaired platelet aggregation and sustained bleeding in mice lacking the fibrinogen motif bound by integrin alpha IIb beta 3.

Authors:  K Holmbäck; M J Danton; T T Suh; C C Daugherty; J L Degen
Journal:  EMBO J       Date:  1996-11-01       Impact factor: 11.598

7.  The structure of a receptor with two associating transmembrane domains on the cell surface: integrin alphaIIbbeta3.

Authors:  Jieqing Zhu; Bing-Hao Luo; Patrick Barth; Jack Schonbrun; David Baker; Timothy A Springer
Journal:  Mol Cell       Date:  2009-04-24       Impact factor: 17.970

Review 8.  Platelet GPIIb/IIIa receptor antagonists in human ischemic brain disease.

Authors:  Rüdiger J Seitz; Mario Siebler
Journal:  Curr Vasc Pharmacol       Date:  2008-01       Impact factor: 2.719

9.  Platelet receptor recognition domain on the gamma chain of human fibrinogen and its synthetic peptide analogues.

Authors:  M Kloczewiak; S Timmons; M A Bednarek; M Sakon; J Hawiger
Journal:  Biochemistry       Date:  1989-04-04       Impact factor: 3.162

10.  Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta3.

Authors:  Timothy A Springer; Jianghai Zhu; Tsan Xiao
Journal:  J Cell Biol       Date:  2008-08-18       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.